STOCK TITAN

Ultragenyx to Present at Upcoming Healthcare Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at two upcoming investor conferences. The events include the Stifel Healthcare Conference on November 15, 2022, at 1:50 PM EST in New York and the Jefferies London Healthcare Conference on November 17, 2022, at 10:25 AM GMT. Live and archived webcasts will be available on the company's website for 90 days. Ultragenyx is dedicated to developing novel therapies for serious rare diseases, focusing on unmet medical needs with its diverse portfolio of approved treatments.

Positive
  • None.
Negative
  • None.

NOVATO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the following upcoming investor conferences:

  • Stifel Healthcare Conference on Tuesday, November 15, 2022, at 1:50 PM EST in New York
  • Jefferies London Healthcare Conference on Thursday, November 17, 2022, at 10:25 AM GMT

The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts
Ultragenyx Pharmaceutical Inc.
Investors
Joshua Higa
ir@ultragenyx.com

Media
Jeff Blake
415-612-7784
media@ultragenyx.com


FAQ

What conferences is Ultragenyx Pharmaceutical presenting at in November 2022?

Ultragenyx Pharmaceutical will present at the Stifel Healthcare Conference on November 15, 2022, and the Jefferies London Healthcare Conference on November 17, 2022.

What is the stock symbol for Ultragenyx Pharmaceutical?

The stock symbol for Ultragenyx Pharmaceutical is RARE.

Who will be presenting at the Ultragenyx conferences?

Emil D. Kakkis, M.D., Ph.D., the CEO of Ultragenyx, will be presenting at the conferences.

Where can I access the webcast of Ultragenyx's presentations?

The live and archived webcasts of Ultragenyx's presentations can be accessed on the company's website.

How long will the webcasts for Ultragenyx's presentations be available?

The webcasts will be available for 90 days after the presentations.

Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE

RARE Rankings

RARE Latest News

RARE Stock Data

4.02B
88.07M
3.62%
97.49%
3.62%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NOVATO